Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis is the commonest chronic inflammatory arthritis of childhood, defined as arthritis of unknown cause persisting for at least six weeks with onset before age sixteen.

There are several distinct clinical subtypes: oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and undifferentiated. Each has characteristic clinical features, associated laboratory findings and differing risks of specific complications.

The most notable complication is chronic anterior uveitis, which is potentially sight-threatening. It requires proactive, structured ophthalmological screening regardless of the presence or absence of any ocular symptom.

Contemporary management incorporates early, aggressive treatment with disease-modifying and biologic agents. This has substantially transformed both short and long-term outcomes compared with historical management approaches.

Classification and pathophysiology

• Oligoarticular juvenile idiopathic arthritis, the commonest subtype, is defined by involvement of four or fewer joints within the first six months of disease. It typically affects the larger joints (particularly the knee) in an asymmetric pattern and occurs predominantly in young girls.
• It carries a substantial, well established association with chronic anterior uveitis, particularly in antinuclear antibody positive individuals. This warrants the most intensive ophthalmological screening protocol among the subtypes.
• Polyarticular juvenile idiopathic arthritis is defined by involvement of five or more joints within the first six months of disease. It is further subdivided according to rheumatoid factor status.
• Rheumatoid factor positive disease occurs predominantly in older girls and more closely resembles adult rheumatoid arthritis in its clinical pattern. It generally carries a less favourable prognosis than rheumatoid factor negative disease.
• Systemic juvenile idiopathic arthritis is a distinct, clinically and pathophysiologically different subtype. It has a prominent systemic inflammatory component (including a characteristic quotidian fever pattern and evanescent rash) that frequently precedes or accompanies the arthritis.
• It carries a recognised, serious risk of macrophage activation syndrome, a severe, potentially life-threatening hyperinflammatory complication.
• It is increasingly understood to reflect an underlying autoinflammatory, rather than classically autoimmune, pathophysiology, which distinguishes it mechanistically from the other subtypes.
• Enthesitis-related arthritis combines arthritis and enthesitis (inflammation at tendon or ligament insertion sites). It predominantly affects the lower limb joints in older boys and is part of the broader spondyloarthropathy spectrum.
• It has a recognised association with HLA-B27 positivity and a risk of acute, symptomatic anterior uveitis, in contrast to the characteristically asymptomatic, chronic uveitis pattern associated with oligoarticular disease.

• Joint swelling, warmth and pain, together with morning stiffness and reduced range of motion, are the core arthritic features shared across the subtypes. The pattern of joint involvement (number, distribution and symmetry) varies substantially by subtype.
• Systemic juvenile idiopathic arthritis presents with a characteristic quotidian (once or twice daily) high, spiking fever pattern. A characteristic evanescent, salmon-pink macular rash typically appears during febrile episodes and resolves as the fever settles.
• Lymphadenopathy, hepatosplenomegaly and serositis (including pericarditis) also occur.
• The arthritis itself sometimes emerges only after a period of these prominent systemic features. This occasionally causes initial diagnostic difficulty, with consideration of an alternative systemic inflammatory or infective process before the arthritic component becomes apparent.
• Macrophage activation syndrome is a serious, potentially life-threatening complication most strongly associated with systemic juvenile idiopathic arthritis. It presents with sudden, marked clinical deterioration, persistent high fever and hepatosplenomegaly.
• Laboratory findings include cytopenias, markedly elevated ferritin, elevated liver enzymes and coagulopathy, reflecting an uncontrolled, hyperinflammatory cytokine cascade. It is a genuine paediatric emergency requiring urgent recognition and aggressive treatment.
• Chronic anterior uveitis is the most significant, sight-threatening extra-articular complication across the spectrum. It is characteristically asymptomatic in its early stages, particularly in oligoarticular and antinuclear antibody positive disease.
• The condition can therefore progress silently to significant, irreversible visual complications (including cataract, glaucoma and band keratopathy) unless identified through proactive, structured screening rather than symptomatic presentation. Screening is an essential component of management.
• Growth disturbance is an important additional consideration in children with poorly controlled, longstanding disease. It includes generalised growth impairment, reflecting the combined effect of chronic inflammation and, in some cases, corticosteroid treatment.
• It also includes localised limb length discrepancy or joint deformity, reflecting the direct effect of chronic inflammation on growth plates adjacent to affected joints.

• Diagnosis is established clinically, based on arthritis (joint swelling, or limitation of motion with associated pain or tenderness) persisting for at least six weeks, with onset before age sixteen.
• Careful, full exclusion of alternative causes of childhood arthritis is required. These include infection (septic arthritis and reactive arthritis), malignancy (particularly leukaemia, which can present with joint pain and swelling mimicking arthritis), and other autoimmune or inflammatory conditions.
• Subtype classification is based on the pattern of joint involvement and associated clinical features during the first six months of disease, together with relevant laboratory findings (rheumatoid factor, antinuclear antibody and HLA-B27 status).
• Classification directly informs both prognosis and the associated risk of extra-articular complications, particularly uveitis.
• Inflammatory markers are frequently elevated, particularly in systemic and polyarticular disease, but are not required for diagnosis and may be entirely normal in oligoarticular disease. Normal inflammatory markers do not exclude the diagnosis where the clinical presentation is otherwise compatible.
• Full baseline and structured, ongoing ophthalmological screening (slit lamp examination) is essential in every confirmed case. Screening frequency and duration are determined by subtype, age of onset and antinuclear antibody status, following established, published protocols.
• This reflects the characteristically asymptomatic nature of the associated uveitis and the time-sensitive importance of early detection to prevent irreversible visual complications.

• Nonsteroidal anti-inflammatory drugs provide symptomatic relief and are an appropriate initial treatment component. They are generally insufficient as sole treatment for the great majority of confirmed cases, given the importance of disease-modifying treatment to prevent long-term joint damage.
• Intra-articular corticosteroid injection is a highly effective, first-line treatment for oligoarticular disease specifically. It frequently produces prolonged, sometimes sustained remission of the affected joint or joints.
• Methotrexate is standard first-line disease-modifying treatment for polyarticular disease, and for oligoarticular disease not adequately controlled with intra-articular corticosteroid injection alone.
• Biologic agents are important, highly effective options for disease not adequately controlled with methotrexate alone. They include tumour necrosis factor inhibitors and, for specific subtypes and treatment-refractory presentations, interleukin-1 and interleukin-6 inhibitors.
• The interleukin inhibitors are a particularly important, targeted option for systemic juvenile idiopathic arthritis, given its distinct, autoinflammatory pathophysiology. The introduction of this treatment class has substantially changed treatment approach and outcome over recent decades.
• Systemic corticosteroid therapy is used for significant systemic symptoms or as a bridging treatment while disease-modifying therapy takes effect. Minimise cumulative corticosteroid exposure, given the substantial adverse effect burden of prolonged use in a growing, developing population.
• Macrophage activation syndrome requires urgent, aggressive treatment, typically high-dose corticosteroids. For more severe or refractory presentations, add targeted immunosuppressive or biologic treatment (including interleukin-1 inhibition). Deliver treatment in an intensive, closely monitored clinical setting, given the life-threatening severity of this complication.
• Full, structured ophthalmological screening is an essential component of management. Where uveitis is identified, treat promptly and with appropriate intensity: typically topical corticosteroids initially, with systemic immunosuppressive or biologic treatment for more severe or treatment-refractory disease.
• Full, coordinated multidisciplinary management underpins long-term care of this chronic childhood condition. It incorporates physiotherapy and occupational therapy (addressing joint function, range of motion and prevention of contracture), growth and nutritional monitoring, psychosocial support, and structured, ongoing rheumatology follow up.
• Careful, structured transition planning to adult rheumatology services is also needed.
• Contemporary, early and aggressive treatment approaches have substantially improved the proportion of children achieving sustained disease remission compared with historical outcomes.